Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

Rajarshi, Keshav; Khan, Rajni; Singh, Mrityunjay; Ranjan, Tushar; S, Ray; Ray, Shashwati

doi:10.1016/j.gene.2020.145313

Cited by 27 publications

(25 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiviral drugs target specific proteins essential for the viral life cycle and disrupt various stages of viral growth. The antiviral drugs used against common RNA viruses include reverse transcriptase inhibitors (nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitors) RdRp inhibitors, and protease inhibitors (target TMPRSS2 and other viral proteases that are involved in the processing of large polypeptide coded by ORF1) ( Rajarshi et al, 2020 ). However, no evidence-based and clinically demonstrated strategy has been shown for the treatment of COVID-19.…”

Section: Control and Management Of Covid-19mentioning

confidence: 99%

One year update on the COVID-19 pandemic: Where are we now?

Mishra¹,

2021

View full text Add to dashboard Cite

Highlights COVID-19 pandemic has sparked a research revolution to understand the disease and find a cure. The past year has seen rapid advances in understanding the biology of SARS-CoV-2 and developing therapeutics. Three vaccines have recently cleared phase III trials (BNT162b2, Sputnik V, and mRNA-1273 vaccine). At the pandemic's 1-year mark, we summarize information on SARS-CoV-2 gathered in the past year.

show abstract

Section: Control and Management Of Covid-19mentioning

confidence: 99%

One year update on the COVID-19 pandemic: Where are we now?

Mishra¹,

2021

View full text Add to dashboard Cite

show abstract

“…Additionally, M-protein inhibits the interaction of 3-phosphoinositide-dependant protein kinase 1 (PDK1) and protein kinase B (PKB) which resulted in release of caspases which eventually causes cell death 18 . This literature survey revealed that M-protein can be a potential target for limiting and targeting the formation of virions and preventing inflammation in host cells 11,19 . Recent studies have repurposed numerous drug-like candidates against well-known targets of SARS-CoV-2 viz.…”

Section: Introductionmentioning

confidence: 99%

“…Apart from the well-known protein targets (3CL pro , PL pro , RdRp), researchers are now targeting other structural (E, N and M-protein) and accessory proteins of the virus [25][26][27] . Among these proteins the M-protein whose role could be vital for viral entry, replication, assembly and maintenance of the virus envelop along with N, E and S proteins can be a potential targeting strategy for COVID-19 further seeks our attention 11,12,19 . Unfortunately, the 3 dimensional (3D) crystal structure of M-protein is not reported till date in protein data bank (PDB).…”

Section: Introductionmentioning

confidence: 99%

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2

Peele

Kumar

Parate

et al. 2021

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Among the SARS−CoV−2 components, the viral proteases such as main protease (M pro ) and papain-like protease (PL pro ) represent molecules critically important in viral replication [ 70 , 71 ]. Proteases, therefore, also offer a potential target for antiviral therapy [ 72 ]. A plethora of known protease inhibitors (including but not limited to disulfiram, lopinavir/ritonavir, nelfinavir and danoprevir) can be potentially employed in COVID-19 therapy [ 70 ].…”

Section: Erms and Estrogens As Inhibitors Of Sars−cov−2 Proteasesmentioning

confidence: 99%

Estrogen Receptor Modulators in Viral Infections Such as SARS−CoV−2: Therapeutic Consequences

Abramenko

Vellieux

Tesařová

et al. 2021

IJMS

View full text Add to dashboard Cite

COVID−19 is a pandemic respiratory disease caused by the SARS−CoV−2 coronavirus. The worldwide epidemiologic data showed higher mortality in males compared to females, suggesting a hypothesis about the protective effect of estrogens against severe disease progression with the ultimate end being patient’s death. This article summarizes the current knowledge regarding the potential effect of estrogens and other modulators of estrogen receptors on COVID−19. While estrogen receptor activation shows complex effects on the patient’s organism, such as an influence on the cardiovascular/pulmonary/immune system which includes lower production of cytokines responsible for the cytokine storm, the receptor-independent effects directly inhibits viral replication. Furthermore, it inhibits the interaction of IL−6 with its receptor complex. Interestingly, in addition to natural hormones, phytestrogens and even synthetic molecules are able to interact with the estrogen receptor and exhibit some anti-COVID−19 activity. From this point of view, estrogen receptor modulators have the potential to be included in the anti-COVID−19 therapeutic arsenal.

show abstract

Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

Cited by 27 publications

References 89 publications

One year update on the COVID-19 pandemic: Where are we now?

One year update on the COVID-19 pandemic: Where are we now?

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2

Estrogen Receptor Modulators in Viral Infections Such as SARS−CoV−2: Therapeutic Consequences

Contact Info

Product

Resources

About